{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-003808","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.720277+00:00","generated_at":"2026-06-19T05:20:50.290679+00:00","sec_items":["2.05","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Graphite Bio discontinues sickle cell gene therapy nula-cel, cuts workforce 50%, explores strategic alternatives","bullets":["Discontinues development of nula-cel for sickle cell disease; exploring external continuation.","Reduces workforce by approximately 50%; expects severance costs of ~$4.9M in Q2 2023.","Chief Business Officer and Chief Scientific Officer to depart in Q2 2023.","Preliminary unaudited cash, equivalents, and marketable securities of ~$283.5M as of Dec 31, 2022.","Will continue early-stage non-genotoxic conditioning program; board approved restructuring."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-003808","json":"https://secwatch.observer/filing/0000950170-23-003808.json","markdown":"https://secwatch.observer/filing/0000950170-23-003808.md","text":"https://secwatch.observer/filing/0000950170-23-003808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000095017023003808/0000950170-23-003808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000095017023003808/grph-20230216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T05:20:50.290679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de1b49f5a788b4aa64cec9c3c083da26fba6a50c","claim":"LENZ Therapeutics, Inc. announced a restructuring with charges of approximately $4.9 million (approximately 50%).","evidence_excerpt":"Under the Plan, the Company is reducing its workforce by approximately 50%. The Company expects to incur estimated severance and related costs of approximately $4.9 million, which will be recorded primarily in the second quarter of 2023.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017023003808/0000950170-23-003808-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $4.9 million"},{"label":"Headcount","value":"approximately 50%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}